pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,510 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT968Endpoints742BioPharma Dive283BioSpace182Fierce Biotech172onclive165globenewswire health73raps
therapy area
allOncology5633Rare Disease1252Cardiology1059Hematology944Immunology934Vaccines817Pulmonology
  • Veradermics reports first positive efficacy data for oral minoxidil in women with pattern hair loss
    Veradermics announced that its oral formulation of minoxidil demonstrated positive efficacy in a mid‑stage trial involving women with pattern hair loss. The results mark the company's first effica…
    Endpoints · 1mo agoPositive readoutPositive↗ source
  • CVS Caremark settles FTC antitrust case, agreeing to favor lowest-cost insulin on formularies
    CVS Caremark announced a settlement with the Federal Trade Commission that resolves the agency’s antitrust lawsuit alleging the PBM favored higher-priced insulin versions. Under the agreement, Car…
    BioPharma Dive · 1mo agoRegulatoryNeutral↗ source
← prev
page 27 of 61
next →
65
fda recalls37
fda medwatch36
fda press25
787
Psychiatry & CNS692
Ophthalmology348
Endocrinology & Metabolism342
Pain342
Infectious Disease334
  • Avere Therapeutics to go public via reverse merger, secures $320M to advance long-acting psoriasis pill
    Avere Therapeutics, a privately held immunology drug developer, announced a plan to become a public company through a reverse merger with NextCure. The transaction includes $320 million in new cap…
    BioPharma Dive · 1mo agoDealPositive↗ source
  • Biogen's tau-targeting Alzheimer's drug shows cognitive slowing in mid-stage trial
    Biogen reported results from its mid-stage "Celia" trial testing the experimental tau-targeting antibody BIIB080 in patients with early Alzheimer's disease. The study compared three dose levels of…
    BioPharma Dive · 1mo agoPositive readoutPositive↗ source
  • AstraZeneca to acquire worldwide rights to Dizal's lung cancer drug Zegfrovy for $600 million
    AstraZeneca announced it will pay $600 million upfront to Dizal Pharmaceutical for the worldwide development and sales rights to the lung cancer drug Zegfrovy. The agreement gives AstraZeneca full…
    Endpoints · 1mo agoDealNeutral↗ source
  • Celcuity receives FDA approval for Revtorpyk breast cancer therapy
    Celcuity, a small public biotech, announced that the U.S. Food and Drug Administration has cleared its drug Revtorpyk for use in breast cancer patients when combined with fulvestrant. The approval…
    Endpoints · 1mo agoApprovalPositive↗ source
  • Bipartisan Bill to Limit US Biotech Deals with China Remains in Limbo
    A bipartisan bill introduced in the House seeks to bar U.S. biotechnology firms from entering into collaborations or licensing agreements with Chinese companies. The proposal sparked strong reacti…
    Endpoints · 1mo agoRegulatoryNeutral↗ source
  • Live webcast examines why biotech IPOs are gaining momentum again
    Drew Armstrong, executive editor at Endpoints News, announced a live webcast scheduled for July 15 at 12 p.m. ET. The session will feature Parabilis CEO Mathai Mammen and Kailera CEO Ron Renaut, al…
    Endpoints · 1mo agoPositive↗ source
  • Erasca seeks $550M in public offering to fund KRAS drug development
    Erasca announced a public offering targeting $550 million to advance its KRAS-targeted drug program. The biotech said the capital will support ongoing research and potential clinical trials for its…
    Endpoints · 1mo agoDealNeutral↗ source
  • AI drug-discovery startup Chai Discovery raises $400 million in Series C, tripling its valuation
    Chai Discovery, a startup focused on using artificial intelligence for drug discovery, announced a new Series C financing round that brought in $400 million. The capital injection was led by existi…
    Endpoints · 1mo agoDealPositive↗ source
  • Draig Therapeutics secures $65M Series B to advance brain-drug trials
    Draig Therapeutics announced a $65 million Series B financing led by Deep Track Capital, with participation from Janus Henderson Investors, Marshall Wace and other investors. The capital will fund…
    BioPharma Dive · 1mo agoDealPositive↗ source
  • Biogen's tau therapy shows mixed Alzheimer's results, low dose outperforms higher dose
    At the Alzheimer's Association International Conference in London, Biogen presented data on its experimental tau‑targeting therapy for Alzheimer's disease. The trial showed that the drug produced…
    Endpoints · 1mo agoNegative readoutNeutral↗ source
  • Innovent Biologics partners with Spero to advance autoimmune drug candidate beyond GSK antibiotic
    Innovent Biologics has announced a new partnership with Spero, a smaller biopharma firm, to develop an autoimmune drug candidate originating from Suzhou, China. The collaboration follows a series…
    Endpoints · 1mo agoDealPositive↗ source
  • Experts say MDUFA VI draft letter improves program while addressing FDA resource limits
    Industry experts note that the draft commitment letter for the upcoming Medical Device User Fee Amendments (MDUFA VI) offers enhancements over the current framework and takes into account the FDA’s…
    raps · 1mo agoRegulatoryNeutral↗ source
  • Cayman court orders Apple Tree Partners’ general partner to give up control of venture fund
    A Cayman Islands court ruled that Seth Harrison, the general partner of biotech venture firm Apple Tree Partners, must relinquish oversight of the fund. The order could shift management to two cour…
    BioPharma Dive · 1mo agoRegulatoryNegative↗ source
  • California settles with bankrupt Carbon Health, signaling crackdown on digital health workarounds
    At the end of June, California's attorney general reached a settlement with Carbon Health, a clinic operator that has filed for bankruptcy. The settlement follows accusations from the state Justic…
    Endpoints · 1mo agoRegulatoryNegative↗ source
  • Draig Therapeutics raises $65 million Series B to push depression drug targeting synapse repair
    Draig Therapeutics announced it has closed a $65 million Series B financing round that was oversubscribed. The capital will be used to advance its neuropsychiatry pipeline, with the lead program f…
    Endpoints · 1mo agoDealPositive↗ source
  • Lyora Therapeutics launches to revive early-stage genetic eye disease programs from Editas and Biogen
    Lyora Therapeutics announced its formation as a new genetic‑medicine company focused on eye diseases. The firm will take over several early‑stage programs that were previously in the pipelines of E…
    Endpoints · 1mo agoPositive↗ source
  • Former Akero executives launch Avere Therapeutics, unveiling China-sourced pipeline drug and reverse merger plan
    The former leadership team of Akero Therapeutics announced the creation of a new in‑licensing company called Avere Therapeutics. The launch was made public on Tuesday and includes a pipeline drug…
    Endpoints · 1mo agoDealNeutral↗ source
  • Agenus redirects late-stage colorectal trial to pre-surgery setting, shares double; Oxford Ebola vaccine enters Phase 1
    Agenus announced it will stop financially supporting its late-stage trial of the BOT+BAL immunotherapy combination in late-line colorectal cancer. The company will instead use recent $340 million…
    BioPharma Dive · 1mo agoNeutral↗ source
  • FDA issues final guidance for psychedelic drug developers and announces public hearing
    The FDA has completed a set of clinical guidance documents aimed at companies developing psychedelic medicines. The guidance outlines expectations for trial design, safety monitoring, and data col…
    Endpoints · 1mo agoRegulatoryPositive↗ source
  • Freenome's updated blood test shows stronger detection of precancerous lesions, boosting Abbott's market prospects
    Freenome announced that its revised SimpleScreen CRC blood test met both primary and secondary goals in a pivotal validation study. The new data indicate better performance than the earlier version…
    BioPharma Dive · 1mo agoPositive readoutPositive↗ source
  • Q32 Bio’s alopecia drug bempikibart meets Phase 2 goal, driving shares up 80%
    Q32 Bio reported that its experimental alopecia areata therapy, bempikibart, achieved the primary endpoint in the second part of a Phase 2 trial. Two‑fifths of participants grew enough hair to cove…
    BioPharma Dive · 1mo agoPositive readoutPositive↗ source
  • Digital health funding jumps to $7.4 billion in first half of 2026
    Digital health startups secured $7.4 billion in venture capital during the first six months of 2026, according to research firm Rock Health. This represents a $1 billion increase compared with the…
    Endpoints · 1mo agoDealPositive↗ source
  • Biopharma M&A Surge Sets Tone for 2026 Earnings Season
    The biopharma sector is entering the second half of 2026 after a year marked by unusually high merger and acquisition activity. Companies have been busy negotiating and closing deals, signaling con…
    Endpoints · 1mo agoDealNeutral↗ source